CD38 and Miyoshi myopathy: Our meta-analysis suggests that while anti-CD38 monoclonal antibodies may be associated with an increased risk of severe lymphopenia, neutropenic infections, and thrombocytopenia, they also offer improved clinical efficacy in MM treatment.